Literature DB >> 24139152

Choroidal melanocytosis evaluation with enhanced depth imaging optical coherence tomography.

Marco Pellegrini1, Carol L Shields2, Sruthi Arepalli3, Jerry A Shields3.   

Abstract

OBJECTIVE: To assess eyes with unilateral choroidal melanocytosis using enhanced depth imaging (EDI) optical coherence tomography (OCT).
DESIGN: Retrospective, observational case series. PARTICIPANTS: Fifteen patients with unilateral choroidal melanocytosis.
METHODS: Each patient was evaluated with EDI-OCT, and comparison was made of involved versus uninvolved foveal retinal and choroidal layers. MAIN OUTCOME MEASURES: Enhanced depth imaging OCT features of choroidal melanocytosis.
RESULTS: The mean patient age was 28 years (median, 23 years; range, 5-76 years). There were 9 male and 6 female patients. Best-corrected visual acuity ranged from 20/20 to 20/30. All patients had subfoveal involvement with choroidal melanocytosis. Associated features included dermal (n = 6), scleral (n = 9), iris (n = 3), and palate (n = 1) melanocytosis. Spectral domain EDI-OCT revealed normal inner retina (n = 15) and normal outer retina (n = 14). The only retinal abnormality was a defect in both the myoid zone and the ellipsoid junction (n = 1). The affected choroid showed smooth anterior contour (n = 15) and thinned or compressed choriocapillaris (n = 2), thinned (n = 3) or thickened (n = 3) medium vessels, and thinned large vessels (n = 2). The subfoveal choroid was a mean 23% thicker in the involved eye, with a mean thickness of 326.4 μm (median, 326 μm; range, 120-459 μm) compared with 264.4 μm (median, 260 μm; range, 94-462 μm) in the uninvolved eye (P = 0.15). The choroidal perivascular interstitial tissue was 51% thicker in the study eye, enwrapping and silhouetting the medium and large vessels (P = 0.01). The ratio between the perivascular stromal tissue and the subfoveal choroidal thickness was 66% in the study eye and 54% in the normal eye (P = 0.0001). Deep partial (n = 5) or complete (n = 2) tissue shadowing was noted.
CONCLUSIONS: Enhanced depth imaging OCT revealed that choroidal melanocytosis shows increased subfoveal choroidal thickness with an apparent increase in the choroidal perivascular stromal tissue and minimal effect on the overlying retina.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24139152     DOI: 10.1016/j.ophtha.2013.08.030

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

Review 1.  An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota).

Authors:  Solmaz Abdolrahimzadeh; Damiano Maria Pugi; Priscilla Manni; Clemente Maria Iodice; Federico Di Tizio; Flavia Persechino; Gianluca Scuderi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-19       Impact factor: 3.535

2.  Assessment of choroidal thickness in healthy and glaucomatous eyes using swept source optical coherence tomography.

Authors:  Chunwei Zhang; Andrew J Tatham; Felipe A Medeiros; Linda M Zangwill; Zhiyong Yang; Robert N Weinreb
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

Review 3.  Review of spectral domain enhanced depth imaging optical coherence tomography of tumors of the choroid.

Authors:  Carol L Shields; Janet Manalac; Chandana Das; Jarin Saktanasate; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

4.  Effect of Uveal Melanocytes on Choroidal Morphology in Rhesus Macaques and Humans on Enhanced-Depth Imaging Optical Coherence Tomography.

Authors:  Glenn Yiu; Vivian S Vuong; Sharon Oltjen; David Cunefare; Sina Farsiu; Laura Garzel; Jeffrey Roberts; Sara M Thomasy
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-10-01       Impact factor: 4.799

5.  Correlation Between Hyperreflective Foci in the Choroid and Choroidal Discoloration in Vogt-Koyanagi-Harada Disease.

Authors:  Young Ho Kim; Ariunaa Togloom; Jaeryung Oh
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.